Clinically, the markedly higher LDL-C associated with LDLR mutations (50% higher median LDL than seen in APOB carriers) highlights the need for especially aggressive lipid-lowering therapy in LDLR-related FH to prevent atherosclerosis [93]. This evidence concerns the gene APOB and atherosclerosis.